Hyun Eric, Bolla Manlio, Steinhoff Martin, Wallace John L, Soldato Piero Del, Vergnolle Nathalie
Mucosal Inflammation Research Group, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada.
Br J Pharmacol. 2004 Nov;143(5):618-25. doi: 10.1038/sj.bjp.0705854. Epub 2004 Aug 16.
1 The concept that nitric oxide (NO) release can be beneficial in inflammatory conditions has raised more attention in the recent years, particularly with the development of nitric oxide-releasing anti-inflammatory drugs. There is considerable evidence that NO is capable of enhancing the anti-inflammatory benefits of conventional anti-inflammatory drugs. 2 Since hydrocortisone is the most widely used anti-inflammatory drug for the treatment of skin inflammation, we compared the anti-inflammatory effects of hydrocortisone to an NO-releasing derivative of hydrocortisone, NCX 1022, in a murine model of irritant contact dermatitis, induced by epidermal application of benzalkonium chloride. 3 Topical pre- and post-treatment with NCX 1022 (3 nmol) in C57BL6 mice not only reduced ear oedema formation in a dose-dependent manner, but also was significantly more effective than the parent compound during the initial stages of inflammation (from 1 to 5 h). NCX 1022, but not hydrocortisone, significantly inhibited granulocyte recruitment (tissue myeloperoxidase activity). Histological samples of mouse ears treated with NCX 1022 showed significant reduction in both the number of infiltrated cells and disruption of the tissue architecture compared to hydrocortisone-treated tissues. 4 With intravital microscopy, we observed that both pre- and post-treatments with NCX 1022 were more effective than hydrocortisone in terms of inhibiting benzalkonium chloride-induced leukocyte adhesion to the endothelium, without affecting the flux of rolling leukocytes or venule diameter. 5 These results suggest that by releasing NO, NCX 1022 modulates one of the early events of skin inflammation: the recruitment of leukocytes to the site of inflammation. Overall, we have shown that NO-hydrocortisone provided faster and greater protective effects, reducing major inflammatory parameters (leukocyte adhesion and recruitment, oedema formation, tissue disruption) compared to its parental compound.
1 近年来,一氧化氮(NO)释放可能对炎症性疾病有益这一概念受到了更多关注,尤其是随着一氧化氮释放型抗炎药物的发展。有大量证据表明,NO能够增强传统抗炎药物的抗炎效果。2 由于氢化可的松是治疗皮肤炎症最广泛使用的抗炎药物,我们在由表皮涂抹苯扎氯铵诱导的刺激性接触性皮炎小鼠模型中,比较了氢化可的松与氢化可的松的一氧化氮释放衍生物NCX 1022的抗炎作用。3 在C57BL6小鼠中,用NCX 1022(3 nmol)进行局部预处理和后处理,不仅以剂量依赖的方式减少了耳部水肿的形成,而且在炎症初期(1至5小时)比母体化合物显著更有效。NCX 1022而非氢化可的松显著抑制粒细胞募集(组织髓过氧化物酶活性)。与氢化可的松处理的组织相比,用NCX 1022处理的小鼠耳部组织学样本显示浸润细胞数量和组织结构破坏均显著减少。4 通过活体显微镜观察,我们发现,在抑制苯扎氯铵诱导的白细胞与内皮细胞黏附方面,NCX 1022的预处理和后处理均比氢化可的松更有效,且不影响滚动白细胞的流量或小静脉直径。5 这些结果表明,通过释放NO,NCX 1022调节了皮肤炎症的早期事件之一:白细胞向炎症部位的募集。总体而言,我们已经表明,与母体化合物相比,一氧化氮 - 氢化可的松提供了更快且更强的保护作用,减少了主要炎症参数(白细胞黏附和募集、水肿形成、组织破坏)。